195 related articles for article (PubMed ID: 33782049)
41. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus.
Weston AP; Krmpotich PT; Cherian R; Dixon A; Topalosvki M
Am J Gastroenterol; 1997 Mar; 92(3):407-13. PubMed ID: 9068459
[TBL] [Abstract][Full Text] [Related]
42. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus.
Gossner L; May A; Stolte M; Seitz G; Hahn EG; Ell C
Gastrointest Endosc; 1999 Jan; 49(1):8-12. PubMed ID: 9869716
[TBL] [Abstract][Full Text] [Related]
43. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
44. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
[TBL] [Abstract][Full Text] [Related]
45. Adenocarcinoma arising in Barrett's esophagus.
Ovaska J; Miettinen M; Kivilaakso E
Dig Dis Sci; 1989 Sep; 34(9):1336-9. PubMed ID: 2766899
[TBL] [Abstract][Full Text] [Related]
46. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
47. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
48. Screening for Barrett's esophagus.
Zakko L; Lutzke L; Wang KK
Minerva Med; 2017 Feb; 108(1):28-42. PubMed ID: 27792223
[TBL] [Abstract][Full Text] [Related]
49. Dysplasia in Random Biopsies from Barrett's Surveillance Is an Important Marker for More Severe Pathology.
Noordzij IC; Van Loon van de Ende MCM; Curvers WL; van Lijnschoten G; Huysentruyt CJ; Schoon EJ
Dig Dis Sci; 2021 Jun; 66(6):1957-1964. PubMed ID: 32661766
[TBL] [Abstract][Full Text] [Related]
50. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
Bresalier RS
Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
[TBL] [Abstract][Full Text] [Related]
51. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
[TBL] [Abstract][Full Text] [Related]
52. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus.
Larghi A; Lightdale CJ; Memeo L; Bhagat G; Okpara N; Rotterdam H
Gastrointest Endosc; 2005 Jul; 62(1):16-23. PubMed ID: 15990814
[TBL] [Abstract][Full Text] [Related]
53. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Konturek PC; Nikiforuk A; Kania J; Raithel M; Hahn EG; Mühldorfer S
Dig Dis Sci; 2004 Aug; 49(7-8):1075-83. PubMed ID: 15387324
[TBL] [Abstract][Full Text] [Related]
54. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
[TBL] [Abstract][Full Text] [Related]
55. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
56. The Present Status and Future of Barrett's Esophageal Adenocarcinoma in Japan.
Nishi T; Makuuchi H; Ozawa S; Shimada H; Chino O
Digestion; 2019; 99(2):185-190. PubMed ID: 30481763
[TBL] [Abstract][Full Text] [Related]
57. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
Incarbone R; Bonavina L; Bassi F; Peracchia A
Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
[TBL] [Abstract][Full Text] [Related]
58. Endoscopic therapy of esophageal premalignancy and early malignancy.
Nealis TB; Washington K; Keswani RN
J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
[TBL] [Abstract][Full Text] [Related]
59. High-grade dysplasia within Barrett's esophagus: controversies regarding clinical opinions and approaches.
Al-Kasspooles MF; Hill HC; Nava HR; Smith JL; Douglass HO; Gibbs JF
Ann Surg Oncol; 2002 Apr; 9(3):222-7. PubMed ID: 11923127
[TBL] [Abstract][Full Text] [Related]
60. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]